数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Jonathan J. Mazelsky Director and President and Chief Executive Officer 63 978.84万美元 8.15 2024-04-01
Sam Samad Independent Director 54 31.73万美元 未持股 2024-04-01
Asha S. Collins Independent Director 48 30.98万美元 0.03 2024-04-01
Irene Chang Britt -- Independent Director -- 未披露 未持股 2024-04-01
Bruce L. Claflin Independent Director 73 34.23万美元 0.19 2024-04-01
Jonathan W. Ayers Non-Employee Director 68 30.98万美元 57.76 2024-04-01
Stuart M. Essig Independent Director 62 32.48万美元 0.06 2024-04-01
Lawrence D. Kingsley Independent Non-Executive Board Chair 61 46.99万美元 0.75 2024-04-01
M. Anne Szostak Independent Director 73 34.23万美元 0.63 2024-04-01
Sophie V. Vandebroek Independent Director 62 30.98万美元 0.87 2024-04-01
Daniel M. Junius Independent Director 71 33.48万美元 0.26 2024-04-01

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Jonathan J. Mazelsky Director and President and Chief Executive Officer 63 978.84万美元 8.15 2024-04-01
Sharon E. Underberg Executive Vice President, General Counsel and Corporate Secretary 62 188.11万美元 未持股 2024-04-01
Tina Hunt Executive Vice President, Strategy, Sector Development and Global Operations 56 253.79万美元 1.18 2024-04-01
Michael J. Lane Executive Vice President and General Manager, Global Reference Laboratories and Information Technology 56 254.12万美元 0.70 2024-04-01
Martin Smith Executive Vice President and Chief Technology Officer 56 未披露 未持股 2024-04-01
Michael P. Johnson Senior Vice President and Chief Human Resources Officer 47 未披露 未持股 2024-04-01
Brian P. McKeon Executive Vice President, Chief Financial Officer and Treasurer 62 351.08万美元 2.92 2024-04-01

董事简历

中英对照 |  中文 |  英文
Jonathan J. Mazelsky

Jonathan J. Mazelsky,自2019年10月起担任IDEXX Laboratories, Inc.的总裁兼首席执行官。在此之前,mazelsky先生于2019年6月至2019年10月担任IDEXX的临时总裁兼首席执行官,并于2012年8月至2019年6月担任执行副总裁,负责IDEXX北美Companion Animal Group 商业组织和创新组合的关键要素,包括IDEXX VetLab内部诊断、诊断成像、兽医软件和服务、快速检测和远程医疗业务线。加入IDEXX之前,他曾担任Philips Healthcare (Royal Philips Electronics(现命名为Royal Philips)的子公司)的计算机断层扫描、核医学和放射治疗规划高级副总裁兼总经理(从2010年到2012年)。在此之前,从2001年开始,他在Philips任职期间担任了一系列其他领导职务,并承担了越来越多的责任。加入Philips之前,他曾任职Agilent Technologies,从2000年到2002年担任执行主管,领导将Agilent的医疗保健集团整合到Philips。1997年至2000年,他还担任Agilent Technologies的医疗耗材业务部总经理。从1988年到1996年,他在Hewlett Packard担任财务、营销和商业规划方面的多个职位。他持有罗切斯特大学(University of Rochester)数学学士学位和芝加哥大学(University of Chicago)工商管理硕士学位。


Jonathan J. Mazelsky,has served as President and CEO of IDEXX since October 2019. Prior to that, Mr. Mazelsky served as Idexx Laboratories, Inc. Interim President and CEO from June 2019 to October 2019, and he was an Executive Vice President responsible for Idexx Laboratories, Inc. North American Companion Animal Group Commercial Organization and key elements of the innovation portfolio, including Idexx Laboratories, Inc. IDEXX VetLab in-house diagnostics, Diagnostic Imaging, Veterinary Software and Services, Rapid Assay and Telemedicine lines of business, from August 2012 to June 2019. Before joining IDEXX, Mr. Mazelsky was a Senior Vice President and General Manager from 2010 to 2012 of Computed Tomography, Nuclear Medicine and Radiation Therapy Planning at Philips Healthcare, a subsidiary of Royal Philips Electronics (now named Royal Philips). Previously he held a series of other leadership roles with increasing responsibilities during his tenure at Philips beginning in 2001. Prior to joining Philips, Mr. Mazelsky was at Agilent Technologies, where he was an Executive in Charge from 2000 to 2002, leading the integration of Agilent's Healthcare Group into Philips. He also served as a General Manager of the Medical Consumables Business Unit at Agilent Technologies from 1997 to 2000. From 1988 to 1996, Mr. Mazelsky held a number of roles at Hewlett Packard in finance, marketing and business planning. Mr. Mazelsky holds an undergraduate degree in Mathematics from the University of Rochester and an MBA from the University of Chicago.
Jonathan J. Mazelsky,自2019年10月起担任IDEXX Laboratories, Inc.的总裁兼首席执行官。在此之前,mazelsky先生于2019年6月至2019年10月担任IDEXX的临时总裁兼首席执行官,并于2012年8月至2019年6月担任执行副总裁,负责IDEXX北美Companion Animal Group 商业组织和创新组合的关键要素,包括IDEXX VetLab内部诊断、诊断成像、兽医软件和服务、快速检测和远程医疗业务线。加入IDEXX之前,他曾担任Philips Healthcare (Royal Philips Electronics(现命名为Royal Philips)的子公司)的计算机断层扫描、核医学和放射治疗规划高级副总裁兼总经理(从2010年到2012年)。在此之前,从2001年开始,他在Philips任职期间担任了一系列其他领导职务,并承担了越来越多的责任。加入Philips之前,他曾任职Agilent Technologies,从2000年到2002年担任执行主管,领导将Agilent的医疗保健集团整合到Philips。1997年至2000年,他还担任Agilent Technologies的医疗耗材业务部总经理。从1988年到1996年,他在Hewlett Packard担任财务、营销和商业规划方面的多个职位。他持有罗切斯特大学(University of Rochester)数学学士学位和芝加哥大学(University of Chicago)工商管理硕士学位。
Jonathan J. Mazelsky,has served as President and CEO of IDEXX since October 2019. Prior to that, Mr. Mazelsky served as Idexx Laboratories, Inc. Interim President and CEO from June 2019 to October 2019, and he was an Executive Vice President responsible for Idexx Laboratories, Inc. North American Companion Animal Group Commercial Organization and key elements of the innovation portfolio, including Idexx Laboratories, Inc. IDEXX VetLab in-house diagnostics, Diagnostic Imaging, Veterinary Software and Services, Rapid Assay and Telemedicine lines of business, from August 2012 to June 2019. Before joining IDEXX, Mr. Mazelsky was a Senior Vice President and General Manager from 2010 to 2012 of Computed Tomography, Nuclear Medicine and Radiation Therapy Planning at Philips Healthcare, a subsidiary of Royal Philips Electronics (now named Royal Philips). Previously he held a series of other leadership roles with increasing responsibilities during his tenure at Philips beginning in 2001. Prior to joining Philips, Mr. Mazelsky was at Agilent Technologies, where he was an Executive in Charge from 2000 to 2002, leading the integration of Agilent's Healthcare Group into Philips. He also served as a General Manager of the Medical Consumables Business Unit at Agilent Technologies from 1997 to 2000. From 1988 to 1996, Mr. Mazelsky held a number of roles at Hewlett Packard in finance, marketing and business planning. Mr. Mazelsky holds an undergraduate degree in Mathematics from the University of Rochester and an MBA from the University of Chicago.
Sam Samad

Sam Samad自2017年1月以来一直担任Illumina,Inc.的高级副总裁兼首席财务官。在加入Illumina之前,Samad先生在2007年11月至2017年1月期间担任Cardinal Health的多个高级领导职务,包括高级副总裁和公司财务主管 从2012年2月至2017年1月,负责Cardinal Health在中国的业务。 他曾于2009年至2012年担任Cardinal制药部门的高级副总裁兼首席财务官,还担任过医疗保健供应链服务副总裁。 他还曾在礼来公司和百事可乐公司担任财务职务。萨马德先生在黎巴嫩贝鲁特美国大学获得工商管理学士学位,并在加拿大汉密尔顿的麦克马斯特大学获得工商管理硕士学位。


Sam Samad,has served as Executive Vice President and Chief Financial Officer of Quest Diagnostics Incorporated since July 2022. Before joining Quest Diagnostics, he was Senior Vice President and Chief Financial Officer of Illumina, Inc. from January 2017 to July 2022. Mr. Samad held several senior leadership positions at Cardinal Health between November 2007 and January 2017, including Senior Vice President and Corporate Treasurer from February 2012 to January 2017, with leadership responsibility for Cardinal Health's China business. He was previously Senior Vice President and Chief Financial Officer for the pharmaceutical segment of Cardinal from 2009 to 2012, and Vice President, Healthcare Supply Chain Services. He also previously held finance roles at Eli Lilly and Pepsico Inc. Mr. Samad received his undergraduate degree in Business Administration from the American University of Beirut in Lebanon and his MBA from McMaster University in Hamilton, Canada.
Sam Samad自2017年1月以来一直担任Illumina,Inc.的高级副总裁兼首席财务官。在加入Illumina之前,Samad先生在2007年11月至2017年1月期间担任Cardinal Health的多个高级领导职务,包括高级副总裁和公司财务主管 从2012年2月至2017年1月,负责Cardinal Health在中国的业务。 他曾于2009年至2012年担任Cardinal制药部门的高级副总裁兼首席财务官,还担任过医疗保健供应链服务副总裁。 他还曾在礼来公司和百事可乐公司担任财务职务。萨马德先生在黎巴嫩贝鲁特美国大学获得工商管理学士学位,并在加拿大汉密尔顿的麦克马斯特大学获得工商管理硕士学位。
Sam Samad,has served as Executive Vice President and Chief Financial Officer of Quest Diagnostics Incorporated since July 2022. Before joining Quest Diagnostics, he was Senior Vice President and Chief Financial Officer of Illumina, Inc. from January 2017 to July 2022. Mr. Samad held several senior leadership positions at Cardinal Health between November 2007 and January 2017, including Senior Vice President and Corporate Treasurer from February 2012 to January 2017, with leadership responsibility for Cardinal Health's China business. He was previously Senior Vice President and Chief Financial Officer for the pharmaceutical segment of Cardinal from 2009 to 2012, and Vice President, Healthcare Supply Chain Services. He also previously held finance roles at Eli Lilly and Pepsico Inc. Mr. Samad received his undergraduate degree in Business Administration from the American University of Beirut in Lebanon and his MBA from McMaster University in Hamilton, Canada.
Asha S. Collins

Asha S. Collins自2018年5月起担任Roche Holding A.G。子公司Genentech,Inc.的美国临床业务主管。加入Genentech之前,Collins博士于2014年9月至2018年3月在McKesson公司担任多个高级领导职位,包括2015年11月至2018年3月担任临床采购和业务开发副总裁,2014年9月至2015年11月担任战略和业务开发高级总监。她曾于2011年至2014年担任Quintiles的首席顾问,并于2008年至2011年担任Deloitte Consulting的经理。2019年7月,Collins博士被阿斯彭研究所选为健康创新者研究员。Collins博士拥有匹兹堡大学的生物学学士学位和威斯康星大学麦迪逊分校的癌症生物学和微生物学博士学位。


Asha S. Collins,has served as General Manager of Biobanks at DNAnexus, Inc. since August 2021. Previously, Dr. Collins served as the Head of U.S. Clinical Operations at Genentech, Inc., a subsidiary of Roche Holding A.G., from May 2018 to June 2021. Prior to joining Genentech, Dr. Collins held several senior leadership positions at McKesson Corporation between September 2014 and March 2018, including Vice President of Clinical Sourcing and Business Development from November 2015 to March 2018 and Senior Director, Corporate Strategy and Business Development from September 2014 to November 2015. She was previously Principal Consultant at Quintiles from 2011 to 2014 and Manager at Deloitte Consulting from 2008 to 2011. In July 2019, Dr. Collins was selected as a Health Innovators Fellow by The Aspen Institute. Dr. Collins holds an undergraduate degree in Biology from the University of Pittsburgh and a PhD in Cancer Biology and Microbiology from the University of Wisconsin-Madison.
Asha S. Collins自2018年5月起担任Roche Holding A.G。子公司Genentech,Inc.的美国临床业务主管。加入Genentech之前,Collins博士于2014年9月至2018年3月在McKesson公司担任多个高级领导职位,包括2015年11月至2018年3月担任临床采购和业务开发副总裁,2014年9月至2015年11月担任战略和业务开发高级总监。她曾于2011年至2014年担任Quintiles的首席顾问,并于2008年至2011年担任Deloitte Consulting的经理。2019年7月,Collins博士被阿斯彭研究所选为健康创新者研究员。Collins博士拥有匹兹堡大学的生物学学士学位和威斯康星大学麦迪逊分校的癌症生物学和微生物学博士学位。
Asha S. Collins,has served as General Manager of Biobanks at DNAnexus, Inc. since August 2021. Previously, Dr. Collins served as the Head of U.S. Clinical Operations at Genentech, Inc., a subsidiary of Roche Holding A.G., from May 2018 to June 2021. Prior to joining Genentech, Dr. Collins held several senior leadership positions at McKesson Corporation between September 2014 and March 2018, including Vice President of Clinical Sourcing and Business Development from November 2015 to March 2018 and Senior Director, Corporate Strategy and Business Development from September 2014 to November 2015. She was previously Principal Consultant at Quintiles from 2011 to 2014 and Manager at Deloitte Consulting from 2008 to 2011. In July 2019, Dr. Collins was selected as a Health Innovators Fellow by The Aspen Institute. Dr. Collins holds an undergraduate degree in Biology from the University of Pittsburgh and a PhD in Cancer Biology and Microbiology from the University of Wisconsin-Madison.
Irene Chang Britt
暂无中文简介

暂无英文简介
暂无中文简介
暂无英文简介
Bruce L. Claflin

Bruce L. Claflin 自2006年8月以来一直担任Ciena的董事。从2001年1月到2006年2月退休,Claflin先生一直担任3Com Corporation 的总裁兼首席执行官。Claflin先生在1998年8月作为总裁兼首席运营官加入了3Com公司。在加入3Com前,Claflin先生担任 Digital Equipment Corporation的销售和营销高级副总裁兼总经理。Claflin先生在IBM工作了22年,他在那里担任各种销售、营销和管理职位,包括担任IBM个人电脑( IBM PC Company)全球研发、产品和品牌管理公司总经理,以及担任IBM个人电脑公司( IBM PC Company)美洲总裁。Claflin先生是Advanced Micro Devices AMD的董事会成员。他目前是该公司董事会主席和该公司的提名和治理委员会主席。


Bruce L. Claflin,served as President, Chief Executive Officer and a member of the board of directors of 3Com Corporation from January 2001 until his retirement in 2006, and he served as President and Chief Operating Officer of 3Com from August 1998 to January 2001. Before joining 3Com, Mr. Claflin worked at Digital Equipment Corporation as Senior Vice President, Sales and Marketing from 1997 to 1998 and as Vice President and General Manager of the PC Business Unit from 1995 to 1997. Before joining Digital Equipment Corporation, Mr. Claflin worked at IBM for 22 years, where he held senior management positions in sales, marketing, research and development and manufacturing. Mr. Claflin holds an undergraduate degree in Political Science from Pennsylvania State University.
Bruce L. Claflin 自2006年8月以来一直担任Ciena的董事。从2001年1月到2006年2月退休,Claflin先生一直担任3Com Corporation 的总裁兼首席执行官。Claflin先生在1998年8月作为总裁兼首席运营官加入了3Com公司。在加入3Com前,Claflin先生担任 Digital Equipment Corporation的销售和营销高级副总裁兼总经理。Claflin先生在IBM工作了22年,他在那里担任各种销售、营销和管理职位,包括担任IBM个人电脑( IBM PC Company)全球研发、产品和品牌管理公司总经理,以及担任IBM个人电脑公司( IBM PC Company)美洲总裁。Claflin先生是Advanced Micro Devices AMD的董事会成员。他目前是该公司董事会主席和该公司的提名和治理委员会主席。
Bruce L. Claflin,served as President, Chief Executive Officer and a member of the board of directors of 3Com Corporation from January 2001 until his retirement in 2006, and he served as President and Chief Operating Officer of 3Com from August 1998 to January 2001. Before joining 3Com, Mr. Claflin worked at Digital Equipment Corporation as Senior Vice President, Sales and Marketing from 1997 to 1998 and as Vice President and General Manager of the PC Business Unit from 1995 to 1997. Before joining Digital Equipment Corporation, Mr. Claflin worked at IBM for 22 years, where he held senior management positions in sales, marketing, research and development and manufacturing. Mr. Claflin holds an undergraduate degree in Political Science from Pennsylvania State University.
Jonathan W. Ayers

Jonathan W. Ayers,自2002年1月起担任IDEXX的董事长、总裁和首席执行官。在加入IDEXX之前,Ayers先生曾在United Technologies Corporation(为全球航空航天和建筑行业的顾客提供高科技产品和支持服务)及其业务单元Carrier Corporation担任多个职位。1999年至2001年,Ayers先生是Carrier Corporation的总裁,后来成为United Technologies的最大业务单元,以及商业和住宅空调系统和设备世界最大的制造商及商业和运输制冷设备的领先生产商。1997年至1999年,Ayers先生是United Technologies的战略计划副总裁。在他在United Technologies任职期间,Ayers先生在领导一个全球业务单元中获得了重要运营经验;培养了管理、金融和战略计划能力;获得了并购整合、线和国际业务、市场营销和产品开发方面的经验。在加入United Technologies之前,1986年至1995年,Ayers先生在Morgan Stanley & Co.担任并购和企业财务方面的多个职位。1983年至1986年,Ayers先生在Bain & Company担任战略顾问;1978年至1981年,在IBM’s Data Processing Division担任区域销售组织工作。Ayers先生拥有Yale University的分子生物物理和生物化学的学士学位,1983年毕业于Harvard Business School。


Jonathan W. Ayers,was Idexx Laboratories, Inc. Board Chair from January 2002 to November 2019 and President and CEO from January 2002 to June 2019. After leaving IDEXX executive management in 2019, Mr. Ayers served as Senior Advisor to the Company from November 2019 to July 2021, and since September 2021, he has served as the Board Chair of Panthera Corporation, a non-profit organization devoted to global wild cat conservation. Before joining IDEXX, Mr. Ayers held various executive leadership positions at United Technologies Corporation and its business unit Carrier Corporation from 1995 to 2001. Prior to that, Mr. Ayers held various investment banking positions at Morgan Stanley & Co. for nine years. Mr. Ayers holds an undergraduate degree in Molecular Biophysics and Biochemistry from Yale University and an MBA from Harvard Business School, with high distinction.
Jonathan W. Ayers,自2002年1月起担任IDEXX的董事长、总裁和首席执行官。在加入IDEXX之前,Ayers先生曾在United Technologies Corporation(为全球航空航天和建筑行业的顾客提供高科技产品和支持服务)及其业务单元Carrier Corporation担任多个职位。1999年至2001年,Ayers先生是Carrier Corporation的总裁,后来成为United Technologies的最大业务单元,以及商业和住宅空调系统和设备世界最大的制造商及商业和运输制冷设备的领先生产商。1997年至1999年,Ayers先生是United Technologies的战略计划副总裁。在他在United Technologies任职期间,Ayers先生在领导一个全球业务单元中获得了重要运营经验;培养了管理、金融和战略计划能力;获得了并购整合、线和国际业务、市场营销和产品开发方面的经验。在加入United Technologies之前,1986年至1995年,Ayers先生在Morgan Stanley & Co.担任并购和企业财务方面的多个职位。1983年至1986年,Ayers先生在Bain & Company担任战略顾问;1978年至1981年,在IBM’s Data Processing Division担任区域销售组织工作。Ayers先生拥有Yale University的分子生物物理和生物化学的学士学位,1983年毕业于Harvard Business School。
Jonathan W. Ayers,was Idexx Laboratories, Inc. Board Chair from January 2002 to November 2019 and President and CEO from January 2002 to June 2019. After leaving IDEXX executive management in 2019, Mr. Ayers served as Senior Advisor to the Company from November 2019 to July 2021, and since September 2021, he has served as the Board Chair of Panthera Corporation, a non-profit organization devoted to global wild cat conservation. Before joining IDEXX, Mr. Ayers held various executive leadership positions at United Technologies Corporation and its business unit Carrier Corporation from 1995 to 2001. Prior to that, Mr. Ayers held various investment banking positions at Morgan Stanley & Co. for nine years. Mr. Ayers holds an undergraduate degree in Molecular Biophysics and Biochemistry from Yale University and an MBA from Harvard Business School, with high distinction.
Stuart M. Essig

Stuart M. Essig是Integra的董事会主席。他自2012年1月起担任Integra Lifesciences Holdings Corporation主席,自1997年加入Integra以来担任董事。他于1997年至2012年担任Integra Lifesciences Holdings Corporation首席执行官,并于1997年至2010年担任Integra Lifesciences Holdings Corporation总裁。在加入公司之前,他在高盛公司担任医疗技术业务并购的董事总经理,目前担任Prettybrook Partners LLC的董事总经理。Essig博士是爱德士、SeaSpine Holdings Corporation、Availity LLC、Breg,Inc.的董事会成员,也是Mission Bio的董事长。他曾在St. Jude Medical Corporation、Owens & Minor Inc.、Zimmer Holdings,Inc.和Vital Signs,Inc.的董事会任职。Essig博士还曾在Advamed的执行委员会、提名和治理委员会任职,并担任财务主管。他是总部位于普林斯顿的商业加速器Tigerlabs的创始投资人。他是Wellington Partners Advisory AG的风险合伙人,曾担任TowerBrook Capital Partners的高级顾问,还曾担任Water Street Healthcare Partners的高级顾问。他还参与了几个非营利慈善组织,并不时在这些组织的董事会任职。Essig博士还在普林斯顿大学工程与应用科学学院领导委员会任职。Essig博士持有普林斯顿大学公共和国际事务学院的本科学位,以及芝加哥大学金融经济学博士学位和工商管理硕士学位。


Stuart M. Essig,has served as the Chair of the Board of Directors of Integra LifeSciences Holdings Corporation since 2012, and he first joined Integra's Board of Directors in 1997. In addition, Dr. Essig was Integra's Chief Executive Officer from 1997 until 2012. Since 2012, he has also served as Managing Director of Prettybrook Partners LLC, a family office focused on investing in the healthcare industry. He is a Venture Partner at Wellington Partners Advisory AG, a venture capital firm, and a Senior Advisor to TowerBrook Capital Partners. Before joining Integra, Dr. Essig was a managing director in mergers and acquisitions for Goldman, Sachs and Co., specializing in the medical device, pharmaceutical and biotechnology sectors. Dr. Essig holds an undergraduate degree from the School of Public and International Affairs at Princeton University, and a PhD in Financial Economics and an MBA from the University of Chicago.
Stuart M. Essig是Integra的董事会主席。他自2012年1月起担任Integra Lifesciences Holdings Corporation主席,自1997年加入Integra以来担任董事。他于1997年至2012年担任Integra Lifesciences Holdings Corporation首席执行官,并于1997年至2010年担任Integra Lifesciences Holdings Corporation总裁。在加入公司之前,他在高盛公司担任医疗技术业务并购的董事总经理,目前担任Prettybrook Partners LLC的董事总经理。Essig博士是爱德士、SeaSpine Holdings Corporation、Availity LLC、Breg,Inc.的董事会成员,也是Mission Bio的董事长。他曾在St. Jude Medical Corporation、Owens & Minor Inc.、Zimmer Holdings,Inc.和Vital Signs,Inc.的董事会任职。Essig博士还曾在Advamed的执行委员会、提名和治理委员会任职,并担任财务主管。他是总部位于普林斯顿的商业加速器Tigerlabs的创始投资人。他是Wellington Partners Advisory AG的风险合伙人,曾担任TowerBrook Capital Partners的高级顾问,还曾担任Water Street Healthcare Partners的高级顾问。他还参与了几个非营利慈善组织,并不时在这些组织的董事会任职。Essig博士还在普林斯顿大学工程与应用科学学院领导委员会任职。Essig博士持有普林斯顿大学公共和国际事务学院的本科学位,以及芝加哥大学金融经济学博士学位和工商管理硕士学位。
Stuart M. Essig,has served as the Chair of the Board of Directors of Integra LifeSciences Holdings Corporation since 2012, and he first joined Integra's Board of Directors in 1997. In addition, Dr. Essig was Integra's Chief Executive Officer from 1997 until 2012. Since 2012, he has also served as Managing Director of Prettybrook Partners LLC, a family office focused on investing in the healthcare industry. He is a Venture Partner at Wellington Partners Advisory AG, a venture capital firm, and a Senior Advisor to TowerBrook Capital Partners. Before joining Integra, Dr. Essig was a managing director in mergers and acquisitions for Goldman, Sachs and Co., specializing in the medical device, pharmaceutical and biotechnology sectors. Dr. Essig holds an undergraduate degree from the School of Public and International Affairs at Princeton University, and a PhD in Financial Economics and an MBA from the University of Chicago.
Lawrence D. Kingsley

Lawrence D. Kingsley,2013年10月以来,他担任颇尔公司( Pall Corporation )的主席。2011年10月以来,他担任首席执行官。从2005年到2011年,他担任IDEX Corporation(从事流体和计量技术和健康和科学技术产品的开发、设计和制造的公司)的总裁和首席执行官。他继续担任IDEX的主席直到2011年末。加入IDEX之前,他担任Danaher Corporation、Kollmorgen Corporation和Weidmuller Incorporated的职务,并不断被提拔。从2007年到2012年,他担任库柏工业集团(Cooper Industries,工业电子元件的公司)的董事。他获得威廉玛丽学院 (College of William and Mary)的工商管理硕士学位。


Lawrence D. Kingsley,has served as the independent Non-Executive Board Chair of IDEXX since November 2019, as the Non-Executive Chairman of the Board of Mirion Technologies, Inc. since October 2021 and as an Advisory Director to Berkshire Partners LLC, a Boston-based investment firm, since May 2016. Prior to that Mr. Kingsley served as Chairman of Pall Corporation from 2013 to 2015 and as Chief Executive Officer of Pall Corporation from 2011 to 2015. Before his experience at Pall, Mr. Kingsley was the Chief Executive Officer of IDEX Corporation, a company specializing in fluid and metering technologies, health and science technologies and fire, safety and other diversified products, from 2005 to 2011 and the Chief Operating Officer of IDEX from 2004 to 2005. From 1995 to 2004, he held various positions of increasing responsibility at Danaher Corporation, including Corporate Vice President and Group Executive from March 2004 to August 2004, President of Industrial Controls Group from 2002 to 2004 and President of Motion Group, Special Purpose Systems from 2001 to 2002. Mr. Kingsley holds an undergraduate degree in Industrial Engineering and Management from Clarkson University and an MBA from the College of William and Mary.
Lawrence D. Kingsley,2013年10月以来,他担任颇尔公司( Pall Corporation )的主席。2011年10月以来,他担任首席执行官。从2005年到2011年,他担任IDEX Corporation(从事流体和计量技术和健康和科学技术产品的开发、设计和制造的公司)的总裁和首席执行官。他继续担任IDEX的主席直到2011年末。加入IDEX之前,他担任Danaher Corporation、Kollmorgen Corporation和Weidmuller Incorporated的职务,并不断被提拔。从2007年到2012年,他担任库柏工业集团(Cooper Industries,工业电子元件的公司)的董事。他获得威廉玛丽学院 (College of William and Mary)的工商管理硕士学位。
Lawrence D. Kingsley,has served as the independent Non-Executive Board Chair of IDEXX since November 2019, as the Non-Executive Chairman of the Board of Mirion Technologies, Inc. since October 2021 and as an Advisory Director to Berkshire Partners LLC, a Boston-based investment firm, since May 2016. Prior to that Mr. Kingsley served as Chairman of Pall Corporation from 2013 to 2015 and as Chief Executive Officer of Pall Corporation from 2011 to 2015. Before his experience at Pall, Mr. Kingsley was the Chief Executive Officer of IDEX Corporation, a company specializing in fluid and metering technologies, health and science technologies and fire, safety and other diversified products, from 2005 to 2011 and the Chief Operating Officer of IDEX from 2004 to 2005. From 1995 to 2004, he held various positions of increasing responsibility at Danaher Corporation, including Corporate Vice President and Group Executive from March 2004 to August 2004, President of Industrial Controls Group from 2002 to 2004 and President of Motion Group, Special Purpose Systems from 2001 to 2002. Mr. Kingsley holds an undergraduate degree in Industrial Engineering and Management from Clarkson University and an MBA from the College of William and Mary.
M. Anne Szostak

M. Anne Szostak, 于2004年成立Szostak Partners(行政培训和人力资源咨询公司),她也一直担任其首席执行官。在成立Szostak Partners之前, Szostak女士在 Fleet/Boston Financial Group (一家财富100上市多元化金融服务公司)现为 Bank of America工作了31年。在她在Fleet/Boston的任期内,她在运营和员工管理方面获得了丰富经验,包括担任Fleet-Maine的董事长、总裁和首席执行官,Fleet Bank-Rhode Island的董事长和首席执行官,以及FleetBoston Financial Group的企业执行副总裁和首席人力资源官。Szostak女士在薪酬和治理事务、审计和投资方面上有大量的专业知识,通过她在多家上市公司董事会的20年经验中获得。其中,Szostak女士曾担任或正在担任一下上市公司的董事:Tupperware Brands Corporation(个人和家用物品的直接消费者销售商),自2000年起;Belo Corp.,电视台及其相关网站的拥有者和运营商(2004年至2013年12月公司拍卖);ChoicePoint Corporation, 一家数据整合公司(2005年至2008年公司拍卖);SFN Group, 一个员工解决方案提供商(2005年至2011年公司拍卖);Dr Pepper Snapple Group, Inc., 一家饮料制造商,装瓶商和分销商(自2008年起)。Szostak女士也是几个地方、区域、国家的非盈利性组织的董事。Szostak女士拥有Colby College的学士学位,她也完成了Harvard Business School的几项行政教育项目。


M. Anne Szostak,Founder of Szostak Partners, an executive coaching and human resources consulting firm formed in 2004. As President of Szostak Partners, she provides strategic advice and counsel to clients. Ms. Szostak is a retired executive officer with Fleet/Boston Financial Group (previously a Fortune 100 company, now Bank of America), a diversified financial services company, with 31 years of service, including as Chairman and Chief Executive Officer of Fleet Bank-Rhode Island from 2001 to 2003, Chairman, President and Chief Executive Officer of Fleet-Maine from 1991 to 1994, and Corporate Executive Vice President and Chief Human Resources Officer of FleetBoston Financial Group from 1998 to 2004. Ms. Szostak has extensive experience in executive leadership positions in a large public company and in executive compensation and human resources, in addition to having served on boards of other public companies. Ms. Szostak holds an undergraduate degree from Colby College, and she has completed several executive education programs at Harvard Business School.
M. Anne Szostak, 于2004年成立Szostak Partners(行政培训和人力资源咨询公司),她也一直担任其首席执行官。在成立Szostak Partners之前, Szostak女士在 Fleet/Boston Financial Group (一家财富100上市多元化金融服务公司)现为 Bank of America工作了31年。在她在Fleet/Boston的任期内,她在运营和员工管理方面获得了丰富经验,包括担任Fleet-Maine的董事长、总裁和首席执行官,Fleet Bank-Rhode Island的董事长和首席执行官,以及FleetBoston Financial Group的企业执行副总裁和首席人力资源官。Szostak女士在薪酬和治理事务、审计和投资方面上有大量的专业知识,通过她在多家上市公司董事会的20年经验中获得。其中,Szostak女士曾担任或正在担任一下上市公司的董事:Tupperware Brands Corporation(个人和家用物品的直接消费者销售商),自2000年起;Belo Corp.,电视台及其相关网站的拥有者和运营商(2004年至2013年12月公司拍卖);ChoicePoint Corporation, 一家数据整合公司(2005年至2008年公司拍卖);SFN Group, 一个员工解决方案提供商(2005年至2011年公司拍卖);Dr Pepper Snapple Group, Inc., 一家饮料制造商,装瓶商和分销商(自2008年起)。Szostak女士也是几个地方、区域、国家的非盈利性组织的董事。Szostak女士拥有Colby College的学士学位,她也完成了Harvard Business School的几项行政教育项目。
M. Anne Szostak,Founder of Szostak Partners, an executive coaching and human resources consulting firm formed in 2004. As President of Szostak Partners, she provides strategic advice and counsel to clients. Ms. Szostak is a retired executive officer with Fleet/Boston Financial Group (previously a Fortune 100 company, now Bank of America), a diversified financial services company, with 31 years of service, including as Chairman and Chief Executive Officer of Fleet Bank-Rhode Island from 2001 to 2003, Chairman, President and Chief Executive Officer of Fleet-Maine from 1991 to 1994, and Corporate Executive Vice President and Chief Human Resources Officer of FleetBoston Financial Group from 1998 to 2004. Ms. Szostak has extensive experience in executive leadership positions in a large public company and in executive compensation and human resources, in addition to having served on boards of other public companies. Ms. Szostak holds an undergraduate degree from Colby College, and she has completed several executive education programs at Harvard Business School.
Sophie V. Vandebroek

Sophie V. Vandebroek,女,自2002年起担任Xerox Corporation(全球领先的业务流程和文档管理企业)的高管。最近,Vandebroek博士担任了Xerox的首席技术官和企业副总裁,自2006年起也担任Xerox Innovation Group的总裁。她负责监管 Xerox在欧洲、亚洲、加拿大和美国的研究中心,以及 Palo Alto Research Center, 她自2008年起担任其独立董事。在她的现任职位之前,2002年至2005年,Vandebroek博士曾担任Xerox的首席工程师,以及 Xerox Engineering Center的副总裁。 Vandebroek博士是Institute of Electrical & Electronics Engineers的成员, Fulbright的成员,和Belgian-American Educational Foundation的成员。 Vandebroek博士入选the Women in Technology International Hall of Fame,和the Royal Flemish Academy for Arts & Sciences. Vandebroek博士拥有超过12项美国专利,担任the Dean of Engineering at the Massachusetts Institute of Technology的顾问。 自2008年起,Vandebroek博士是Analogic Corporation(先进的医学成像和机场安检系统设计商和制造商)的董事。Vandebroek博士拥有比利时鲁汶的 Katholieke Universiteit Leuven的工程学学士和机电工程硕士学位,以及纽约的 Cornell University in Ithaca的电气工程博士学位。董事会成员的经历使她在技术和业务流程方面有了丰富的知识和经验,还有她为大型全球企业提供的创新性和管理平衡研发投资组合的追踪记录。


Sophie V. Vandebroek,has served as founder and owner of Strategic Vision Ventures LLC since February 2021. Previously, Dr. Vandebroek was the inaugural visiting scholar at the Massachusetts Institute of Technology School of Engineering for the 2019-2020 academic year; Vice President, Emerging Technology Partnerships for International Business Machines Corporation (IBM) from August 2018 to August 2019; and Chief Operating Officer - IBM Research from January 2017 to August 2018. Prior to joining IBM, she was an executive with Xerox Corporation, where she served as Chief Technology Officer and Corporate Vice President of Xerox Corporation and President of the Xerox Innovation Group from 2006 to 2016 and Chief Engineer of Xerox Corporation from 2002 to 2005. She was also responsible for overseeing Xerox's global research centers, including the Palo Alto Research Center, or PARC Inc. In 2021, Dr. Vandebroek was appointed an honorary Professor at KU Leuven, Belgium. Dr. Vandebroek is the Chair of the Advisory Committee of the Flanders AI Research Program, a member of the AI Innovation Board of the Norwegian Research Center for AI and a Fellow of the Institute of Electrical & Electronics Engineers. Dr. Vandebroek holds an undergraduate degree in Engineering and a master's degree in Electro-mechanical Engineering from KU Leuven, Leuven, Belgium, and a PhD in Electrical Engineering from Cornell University.
Sophie V. Vandebroek,女,自2002年起担任Xerox Corporation(全球领先的业务流程和文档管理企业)的高管。最近,Vandebroek博士担任了Xerox的首席技术官和企业副总裁,自2006年起也担任Xerox Innovation Group的总裁。她负责监管 Xerox在欧洲、亚洲、加拿大和美国的研究中心,以及 Palo Alto Research Center, 她自2008年起担任其独立董事。在她的现任职位之前,2002年至2005年,Vandebroek博士曾担任Xerox的首席工程师,以及 Xerox Engineering Center的副总裁。 Vandebroek博士是Institute of Electrical & Electronics Engineers的成员, Fulbright的成员,和Belgian-American Educational Foundation的成员。 Vandebroek博士入选the Women in Technology International Hall of Fame,和the Royal Flemish Academy for Arts & Sciences. Vandebroek博士拥有超过12项美国专利,担任the Dean of Engineering at the Massachusetts Institute of Technology的顾问。 自2008年起,Vandebroek博士是Analogic Corporation(先进的医学成像和机场安检系统设计商和制造商)的董事。Vandebroek博士拥有比利时鲁汶的 Katholieke Universiteit Leuven的工程学学士和机电工程硕士学位,以及纽约的 Cornell University in Ithaca的电气工程博士学位。董事会成员的经历使她在技术和业务流程方面有了丰富的知识和经验,还有她为大型全球企业提供的创新性和管理平衡研发投资组合的追踪记录。
Sophie V. Vandebroek,has served as founder and owner of Strategic Vision Ventures LLC since February 2021. Previously, Dr. Vandebroek was the inaugural visiting scholar at the Massachusetts Institute of Technology School of Engineering for the 2019-2020 academic year; Vice President, Emerging Technology Partnerships for International Business Machines Corporation (IBM) from August 2018 to August 2019; and Chief Operating Officer - IBM Research from January 2017 to August 2018. Prior to joining IBM, she was an executive with Xerox Corporation, where she served as Chief Technology Officer and Corporate Vice President of Xerox Corporation and President of the Xerox Innovation Group from 2006 to 2016 and Chief Engineer of Xerox Corporation from 2002 to 2005. She was also responsible for overseeing Xerox's global research centers, including the Palo Alto Research Center, or PARC Inc. In 2021, Dr. Vandebroek was appointed an honorary Professor at KU Leuven, Belgium. Dr. Vandebroek is the Chair of the Advisory Committee of the Flanders AI Research Program, a member of the AI Innovation Board of the Norwegian Research Center for AI and a Fellow of the Institute of Electrical & Electronics Engineers. Dr. Vandebroek holds an undergraduate degree in Engineering and a master's degree in Electro-mechanical Engineering from KU Leuven, Leuven, Belgium, and a PhD in Electrical Engineering from Cornell University.
Daniel M. Junius

Daniel M. Junius,自2009年1月起担任 has served as President and Chief Executive Officer of ImmunoGen, Inc.(一家生物技术公司,提供有针对性的抗癌疗法)的总裁和首席执行官。在那之前,2008年7月至2008年12月,他曾担任ImmunoGen的总裁、首席运营官和代理首席财务官;2006年至2008年7月,担任执行副总裁和首席财务官;2005年至2006年,担任高级副总裁和首席财务官。自2008年11月起,Junius先生同时也担任ImmunoGen的董事。在加入ImmunoGen之前, Junius先生也曾担任New England Business Service, Inc.(NEBS)(一家B2B直营公司)的执行副总裁和首席财务官,从2002年直到其于2004年被Deluxe Corporation收购;1998年至2002年,担任NEBS的高级副总裁和首席财务官。在NEBS之前,他曾担任Nashua Corporation(一个专业成像纸和标签的产品和服务的生产商和销售商)的副总裁和首席财务官。他于1984年加入Nashua Corporation,在1996年成为该公司首席财务官之前曾担任越来越重要的金融管理职位。Junius先生拥有 Boston College的政治学学士学位,和Northwestern University’s Kellogg School of Management的管理学硕士学位。


Daniel M. Junius,served as President and Chief Executive Officer of ImmunoGen, Inc. from 2009 until his retirement in May 2016. Before that, he served as President and Chief Operating Officer and Acting Chief Financial Officer of ImmunoGen from July 2008 to December 2008, Executive Vice President and Chief Financial Officer from 2006 to July 2008 and Senior Vice President and Chief Financial Officer from 2005 to 2006. Before joining ImmunoGen, Mr. Junius was Executive Vice President and Chief Financial Officer of New England Business Service, Inc. from 2002 until its acquisition by Deluxe Corporation in 2004 and Senior Vice President and Chief Financial Officer of New England Business Service from 1998 to 2002. Before joining New England Business Service, Mr. Junius was Vice President and Chief Financial Officer of Nashua Corporation from 1996 to 1998. Mr. Junius joined Nashua Corporation in 1984 and held various financial management positions of increasing responsibility before becoming Chief Financial Officer. Mr. Junius holds an undergraduate degree in Political Science from Boston College and a master's degree in Management from Northwestern University's Kellogg School of Management.
Daniel M. Junius,自2009年1月起担任 has served as President and Chief Executive Officer of ImmunoGen, Inc.(一家生物技术公司,提供有针对性的抗癌疗法)的总裁和首席执行官。在那之前,2008年7月至2008年12月,他曾担任ImmunoGen的总裁、首席运营官和代理首席财务官;2006年至2008年7月,担任执行副总裁和首席财务官;2005年至2006年,担任高级副总裁和首席财务官。自2008年11月起,Junius先生同时也担任ImmunoGen的董事。在加入ImmunoGen之前, Junius先生也曾担任New England Business Service, Inc.(NEBS)(一家B2B直营公司)的执行副总裁和首席财务官,从2002年直到其于2004年被Deluxe Corporation收购;1998年至2002年,担任NEBS的高级副总裁和首席财务官。在NEBS之前,他曾担任Nashua Corporation(一个专业成像纸和标签的产品和服务的生产商和销售商)的副总裁和首席财务官。他于1984年加入Nashua Corporation,在1996年成为该公司首席财务官之前曾担任越来越重要的金融管理职位。Junius先生拥有 Boston College的政治学学士学位,和Northwestern University’s Kellogg School of Management的管理学硕士学位。
Daniel M. Junius,served as President and Chief Executive Officer of ImmunoGen, Inc. from 2009 until his retirement in May 2016. Before that, he served as President and Chief Operating Officer and Acting Chief Financial Officer of ImmunoGen from July 2008 to December 2008, Executive Vice President and Chief Financial Officer from 2006 to July 2008 and Senior Vice President and Chief Financial Officer from 2005 to 2006. Before joining ImmunoGen, Mr. Junius was Executive Vice President and Chief Financial Officer of New England Business Service, Inc. from 2002 until its acquisition by Deluxe Corporation in 2004 and Senior Vice President and Chief Financial Officer of New England Business Service from 1998 to 2002. Before joining New England Business Service, Mr. Junius was Vice President and Chief Financial Officer of Nashua Corporation from 1996 to 1998. Mr. Junius joined Nashua Corporation in 1984 and held various financial management positions of increasing responsibility before becoming Chief Financial Officer. Mr. Junius holds an undergraduate degree in Political Science from Boston College and a master's degree in Management from Northwestern University's Kellogg School of Management.

高管简历

中英对照 |  中文 |  英文
Jonathan J. Mazelsky

Jonathan J. Mazelsky,自2019年10月起担任IDEXX Laboratories, Inc.的总裁兼首席执行官。在此之前,mazelsky先生于2019年6月至2019年10月担任IDEXX的临时总裁兼首席执行官,并于2012年8月至2019年6月担任执行副总裁,负责IDEXX北美Companion Animal Group 商业组织和创新组合的关键要素,包括IDEXX VetLab内部诊断、诊断成像、兽医软件和服务、快速检测和远程医疗业务线。加入IDEXX之前,他曾担任Philips Healthcare (Royal Philips Electronics(现命名为Royal Philips)的子公司)的计算机断层扫描、核医学和放射治疗规划高级副总裁兼总经理(从2010年到2012年)。在此之前,从2001年开始,他在Philips任职期间担任了一系列其他领导职务,并承担了越来越多的责任。加入Philips之前,他曾任职Agilent Technologies,从2000年到2002年担任执行主管,领导将Agilent的医疗保健集团整合到Philips。1997年至2000年,他还担任Agilent Technologies的医疗耗材业务部总经理。从1988年到1996年,他在Hewlett Packard担任财务、营销和商业规划方面的多个职位。他持有罗切斯特大学(University of Rochester)数学学士学位和芝加哥大学(University of Chicago)工商管理硕士学位。


Jonathan J. Mazelsky,has served as President and CEO of IDEXX since October 2019. Prior to that, Mr. Mazelsky served as Idexx Laboratories, Inc. Interim President and CEO from June 2019 to October 2019, and he was an Executive Vice President responsible for Idexx Laboratories, Inc. North American Companion Animal Group Commercial Organization and key elements of the innovation portfolio, including Idexx Laboratories, Inc. IDEXX VetLab in-house diagnostics, Diagnostic Imaging, Veterinary Software and Services, Rapid Assay and Telemedicine lines of business, from August 2012 to June 2019. Before joining IDEXX, Mr. Mazelsky was a Senior Vice President and General Manager from 2010 to 2012 of Computed Tomography, Nuclear Medicine and Radiation Therapy Planning at Philips Healthcare, a subsidiary of Royal Philips Electronics (now named Royal Philips). Previously he held a series of other leadership roles with increasing responsibilities during his tenure at Philips beginning in 2001. Prior to joining Philips, Mr. Mazelsky was at Agilent Technologies, where he was an Executive in Charge from 2000 to 2002, leading the integration of Agilent's Healthcare Group into Philips. He also served as a General Manager of the Medical Consumables Business Unit at Agilent Technologies from 1997 to 2000. From 1988 to 1996, Mr. Mazelsky held a number of roles at Hewlett Packard in finance, marketing and business planning. Mr. Mazelsky holds an undergraduate degree in Mathematics from the University of Rochester and an MBA from the University of Chicago.
Jonathan J. Mazelsky,自2019年10月起担任IDEXX Laboratories, Inc.的总裁兼首席执行官。在此之前,mazelsky先生于2019年6月至2019年10月担任IDEXX的临时总裁兼首席执行官,并于2012年8月至2019年6月担任执行副总裁,负责IDEXX北美Companion Animal Group 商业组织和创新组合的关键要素,包括IDEXX VetLab内部诊断、诊断成像、兽医软件和服务、快速检测和远程医疗业务线。加入IDEXX之前,他曾担任Philips Healthcare (Royal Philips Electronics(现命名为Royal Philips)的子公司)的计算机断层扫描、核医学和放射治疗规划高级副总裁兼总经理(从2010年到2012年)。在此之前,从2001年开始,他在Philips任职期间担任了一系列其他领导职务,并承担了越来越多的责任。加入Philips之前,他曾任职Agilent Technologies,从2000年到2002年担任执行主管,领导将Agilent的医疗保健集团整合到Philips。1997年至2000年,他还担任Agilent Technologies的医疗耗材业务部总经理。从1988年到1996年,他在Hewlett Packard担任财务、营销和商业规划方面的多个职位。他持有罗切斯特大学(University of Rochester)数学学士学位和芝加哥大学(University of Chicago)工商管理硕士学位。
Jonathan J. Mazelsky,has served as President and CEO of IDEXX since October 2019. Prior to that, Mr. Mazelsky served as Idexx Laboratories, Inc. Interim President and CEO from June 2019 to October 2019, and he was an Executive Vice President responsible for Idexx Laboratories, Inc. North American Companion Animal Group Commercial Organization and key elements of the innovation portfolio, including Idexx Laboratories, Inc. IDEXX VetLab in-house diagnostics, Diagnostic Imaging, Veterinary Software and Services, Rapid Assay and Telemedicine lines of business, from August 2012 to June 2019. Before joining IDEXX, Mr. Mazelsky was a Senior Vice President and General Manager from 2010 to 2012 of Computed Tomography, Nuclear Medicine and Radiation Therapy Planning at Philips Healthcare, a subsidiary of Royal Philips Electronics (now named Royal Philips). Previously he held a series of other leadership roles with increasing responsibilities during his tenure at Philips beginning in 2001. Prior to joining Philips, Mr. Mazelsky was at Agilent Technologies, where he was an Executive in Charge from 2000 to 2002, leading the integration of Agilent's Healthcare Group into Philips. He also served as a General Manager of the Medical Consumables Business Unit at Agilent Technologies from 1997 to 2000. From 1988 to 1996, Mr. Mazelsky held a number of roles at Hewlett Packard in finance, marketing and business planning. Mr. Mazelsky holds an undergraduate degree in Mathematics from the University of Rochester and an MBA from the University of Chicago.
Sharon E. Underberg

Sharon E. Underberg 担任执行副总裁、总法律顾问和公司秘书。在此职位上,她领导 IDEXX 的全球法律、公司治理、合规和公司秘书职能。 Underberg 女士于 2019 年 2 月加入公司,担任公司副总裁,并于 2019 年 3 月担任总法律顾问和公司秘书,她被任命为高级副总裁,自 2021 年 1 月 1 日起生效,并被任命为执行副总裁,自 2022 年 2 月 9 日起生效。在加入 IDEXX 之前,Underberg 女士于 2015 年 1 月至 2019 年 1 月担任柯达伊士曼柯达公司的总法律顾问、秘书和高级副总裁。在此之前,她从 2014 年 9 月起担任柯达的副总法律顾问和法律部副总裁至 2015 年 1 月 2006 年 6 月至 2014 年 9 月担任法律部助理总法律顾问兼副总裁,2004 年 6 月至 2006 年 6 月担任助理秘书。在 1989 年 10 月加入Kodak 之前,Underberg 女士是一名私人执业律师。她拥有布兰代斯大学政治学本科学位和宾夕法尼亚大学法学院法学博士学位。


Sharon E. Underberg,serves as Executive Vice President, General Counsel and Corporate Secretary. In this capacity, she leads IDEXX's global legal, corporate governance, compliance and corporate secretary functions. Ms. Underberg joined the Company in February 2019 as a Corporate Vice President and assumed the roles of General Counsel and Corporate Secretary in March 2019. She was appointed a Senior Vice President effective January 1, 2021, and an Executive Vice President effective February 9, 2022. Prior to joining IDEXX, Ms. Underberg served as General Counsel, Secretary and Senior Vice President of Eastman Kodak Company (Kodak) from January 2015 to January 2019. Prior to that, she served as Kodak's Deputy General Counsel and Vice President, Legal Department, from September 2014 to January 2015, Assistant General Counsel and Vice President, Legal Department, from June 2006 to September 2014, and as Assistant Secretary from June 2004 to June 2006. Prior to joining Kodak in October 1989, Ms. Underberg was an attorney in private practice. She holds an undergraduate degree in Political Science from Brandeis University and a JD from the University of Pennsylvania School of Law.
Sharon E. Underberg 担任执行副总裁、总法律顾问和公司秘书。在此职位上,她领导 IDEXX 的全球法律、公司治理、合规和公司秘书职能。 Underberg 女士于 2019 年 2 月加入公司,担任公司副总裁,并于 2019 年 3 月担任总法律顾问和公司秘书,她被任命为高级副总裁,自 2021 年 1 月 1 日起生效,并被任命为执行副总裁,自 2022 年 2 月 9 日起生效。在加入 IDEXX 之前,Underberg 女士于 2015 年 1 月至 2019 年 1 月担任柯达伊士曼柯达公司的总法律顾问、秘书和高级副总裁。在此之前,她从 2014 年 9 月起担任柯达的副总法律顾问和法律部副总裁至 2015 年 1 月 2006 年 6 月至 2014 年 9 月担任法律部助理总法律顾问兼副总裁,2004 年 6 月至 2006 年 6 月担任助理秘书。在 1989 年 10 月加入Kodak 之前,Underberg 女士是一名私人执业律师。她拥有布兰代斯大学政治学本科学位和宾夕法尼亚大学法学院法学博士学位。
Sharon E. Underberg,serves as Executive Vice President, General Counsel and Corporate Secretary. In this capacity, she leads IDEXX's global legal, corporate governance, compliance and corporate secretary functions. Ms. Underberg joined the Company in February 2019 as a Corporate Vice President and assumed the roles of General Counsel and Corporate Secretary in March 2019. She was appointed a Senior Vice President effective January 1, 2021, and an Executive Vice President effective February 9, 2022. Prior to joining IDEXX, Ms. Underberg served as General Counsel, Secretary and Senior Vice President of Eastman Kodak Company (Kodak) from January 2015 to January 2019. Prior to that, she served as Kodak's Deputy General Counsel and Vice President, Legal Department, from September 2014 to January 2015, Assistant General Counsel and Vice President, Legal Department, from June 2006 to September 2014, and as Assistant Secretary from June 2004 to June 2006. Prior to joining Kodak in October 1989, Ms. Underberg was an attorney in private practice. She holds an undergraduate degree in Political Science from Brandeis University and a JD from the University of Pennsylvania School of Law.
Tina Hunt

Tina Hunt自2020年1月起担任IDEXX执行副总裁兼和全球运营总经理。在此之前,她于2016年11月至2020年1月担任IDEXX公司副总裁,其投资组合包括公司的IDEXX VetLab,诊断成像和远程医疗业务。 Hunt博士于2006年加入IDEXX,担任过各种领导职务,以支持公司强大的创新渠道,最近担任IDEXX VetLab组织的总经理。在担任该职务期间,她领导了针对日益增长和日益复杂的全球市场的市场领先的兽医诊断分析仪和测定法的开发。在加入IDEXX之前,Hunt博士曾在Woodard Curran担任副总裁,领导该公司的诉讼支持业务。她拥有普渡大学(Purdue University)环境工程博士学位,南缅因大学(Southern Maine University)工商管理硕士学位(MBA),并且是斯坦福大学商学院高管人员教育计划的毕业生。


Tina Hunt,2006–present: various leadership and executive roles, including EVP, Strategy, Sector Development and Global Operations since 2023, and EVP, General Manager, Point of Care Diagnostics and Worldwide Operations from 2020 to 2022 at IDEXX Laboratories, Inc., a global leader in veterinary diagnostics and pet healthcare innovation,1996–2006: various leadership and executive roles, including VP at Woodard & Curran Inc., a consulting firm focused on water and environmental projects,1989–1990: Sales Executive, Hindustan Computers, an Indian multinational information technology services and consulting company.Bachelor of Engineering, Civil Engineering, Panjab Engineering College,Master of Science, Environmental Engineering, Purdue University,Doctor of Philosophy, Environmental Engineering, Purdue University,Master of Business Administration, University of Southern Maine.
Tina Hunt自2020年1月起担任IDEXX执行副总裁兼和全球运营总经理。在此之前,她于2016年11月至2020年1月担任IDEXX公司副总裁,其投资组合包括公司的IDEXX VetLab,诊断成像和远程医疗业务。 Hunt博士于2006年加入IDEXX,担任过各种领导职务,以支持公司强大的创新渠道,最近担任IDEXX VetLab组织的总经理。在担任该职务期间,她领导了针对日益增长和日益复杂的全球市场的市场领先的兽医诊断分析仪和测定法的开发。在加入IDEXX之前,Hunt博士曾在Woodard Curran担任副总裁,领导该公司的诉讼支持业务。她拥有普渡大学(Purdue University)环境工程博士学位,南缅因大学(Southern Maine University)工商管理硕士学位(MBA),并且是斯坦福大学商学院高管人员教育计划的毕业生。
Tina Hunt,2006–present: various leadership and executive roles, including EVP, Strategy, Sector Development and Global Operations since 2023, and EVP, General Manager, Point of Care Diagnostics and Worldwide Operations from 2020 to 2022 at IDEXX Laboratories, Inc., a global leader in veterinary diagnostics and pet healthcare innovation,1996–2006: various leadership and executive roles, including VP at Woodard & Curran Inc., a consulting firm focused on water and environmental projects,1989–1990: Sales Executive, Hindustan Computers, an Indian multinational information technology services and consulting company.Bachelor of Engineering, Civil Engineering, Panjab Engineering College,Master of Science, Environmental Engineering, Purdue University,Doctor of Philosophy, Environmental Engineering, Purdue University,Master of Business Administration, University of Southern Maine.
Michael J. Lane

Michael J. Lane,自2020年1月起担任IDEXX的执行副总裁,此前曾担任公司副总裁(2015年7月至2020年1月)和副总裁(2012年至2015年7月)。自2016年11月以来,他一直担任IDEXX全球参考实验室业务的总经理,其投资组合目前还包括公司的全球远程医疗和IDEXX生物分析业务,以及其信息技术部门。在成为Idexx Laboratories, Inc.的总经理之前。2014年6月至2016年11月,他担任公司U.S. Reference Laboratories的总经理。除了负责参考实验室业务外,从2015年7月到2016年12月,Lane先生为公司的SNAP Point-of-Care测试提供战略方向。1999年,他加入IDEXX VetLab组织,在那里他担任各种领导职务,负责商业营销,产品管理和新产品开发,并于2012年至2014年担任总经理。他于1997年加入IDEXX,在IDEXX进入全球参考实验室细分市场时,为诊断实验室服务的战略规划和业务发展提供支持。他持有Middlebury College的国际政治和经济学学士学位,以及Tuck School of Business at Dartmouth College的工商管理硕士学位。


Michael J. Lane,has been an Executive Vice President of IDEXX since January 2020 and previously served as a Corporate Vice President from July 2015 to January 2020 and a Vice President from 2012 to July 2015. He has been the General Manager of IDEXX's Global Reference Laboratories business since November 2016, with a portfolio that also currently includes the Company's worldwide Telemedicine and IDEXX BioAnalytics businesses, as well as its Information Technology department. Prior to becoming the General Manager of Idexx Laboratories, Inc. Global Reference Laboratories business, he served as the General Manager of the Company's U.S. Reference Laboratories from June 2014 to November 2016. In addition to his responsibilities for the Reference Laboratories business, from July 2015 through December 2016, Mr. Lane provided strategic direction for the Company's SNAP Point-of-Care testing. In 1999, he joined the IDEXX VetLab organization, where he held various leadership positions with responsibilities in commercial marketing, product management, and new product development, and served as General Manager from 2012 to 2014. Mr. Lane joined IDEXX in 1997, supporting strategic planning and business development for diagnostic laboratory services as IDEXX entered the global reference laboratory market segment. Mr. Lane holds an undergraduate degree in International Politics and Economics from Middlebury College and an MBA from the Tuck School of Business at Dartmouth College.
Michael J. Lane,自2020年1月起担任IDEXX的执行副总裁,此前曾担任公司副总裁(2015年7月至2020年1月)和副总裁(2012年至2015年7月)。自2016年11月以来,他一直担任IDEXX全球参考实验室业务的总经理,其投资组合目前还包括公司的全球远程医疗和IDEXX生物分析业务,以及其信息技术部门。在成为Idexx Laboratories, Inc.的总经理之前。2014年6月至2016年11月,他担任公司U.S. Reference Laboratories的总经理。除了负责参考实验室业务外,从2015年7月到2016年12月,Lane先生为公司的SNAP Point-of-Care测试提供战略方向。1999年,他加入IDEXX VetLab组织,在那里他担任各种领导职务,负责商业营销,产品管理和新产品开发,并于2012年至2014年担任总经理。他于1997年加入IDEXX,在IDEXX进入全球参考实验室细分市场时,为诊断实验室服务的战略规划和业务发展提供支持。他持有Middlebury College的国际政治和经济学学士学位,以及Tuck School of Business at Dartmouth College的工商管理硕士学位。
Michael J. Lane,has been an Executive Vice President of IDEXX since January 2020 and previously served as a Corporate Vice President from July 2015 to January 2020 and a Vice President from 2012 to July 2015. He has been the General Manager of IDEXX's Global Reference Laboratories business since November 2016, with a portfolio that also currently includes the Company's worldwide Telemedicine and IDEXX BioAnalytics businesses, as well as its Information Technology department. Prior to becoming the General Manager of Idexx Laboratories, Inc. Global Reference Laboratories business, he served as the General Manager of the Company's U.S. Reference Laboratories from June 2014 to November 2016. In addition to his responsibilities for the Reference Laboratories business, from July 2015 through December 2016, Mr. Lane provided strategic direction for the Company's SNAP Point-of-Care testing. In 1999, he joined the IDEXX VetLab organization, where he held various leadership positions with responsibilities in commercial marketing, product management, and new product development, and served as General Manager from 2012 to 2014. Mr. Lane joined IDEXX in 1997, supporting strategic planning and business development for diagnostic laboratory services as IDEXX entered the global reference laboratory market segment. Mr. Lane holds an undergraduate degree in International Politics and Economics from Middlebury College and an MBA from the Tuck School of Business at Dartmouth College.
Martin Smith

Martin Smith ,自2021年8月起担任执行副总裁兼首席技术官。在加入IDEXX之前,他曾担任CyTiVA的副总裁和首席技术官,CyTiVA是DaaHER公司的一部分,从2020年8月到2021年7月。此前,Smith 博士在帕尔公司担任过各种领导职位,职责越来越重,最近一次是在2014年9月至2020年8月担任帕尔公司的首席技术官。Smith 博士曾在Pall担任高级副总裁,2010年至2014年担任Pall研发部副总裁,2008年至2010年担任Pall Medical研发部副总裁,2006年至2008年担任Pall生命科学研发部高级总监。Smith 博士获得了埃塞克斯大学生物科学的本科学位,来自雷丁大学的生物技术硕士学位和伦敦大学学院细胞生物学博士学位。他在分离科学领域拥有多项美国专利。


Martin Smith,has been Executive Vice President and Chief Technology Officer since August 2021. Prior to joining IDEXX, he served as Vice President and Chief Technology Officer of Cytiva, which is part of Danaher Corporation, from August 2020 to July 2021. Previously, Dr. Smith held various leadership positions with increasing responsibilities at Pall Corporation, most recently serving as Pall's Chief Technology Officer from September 2014 to August 2020. Dr. Smith's prior roles at Pall included Senior Vice President, Pall R&D from 2010 to 2014, Vice President, Research & Development, Pall Medical from 2008 to 2010 and Senior Director, Pall Life Science R&D from 2006 to 2008. Dr. Smith received an undergraduate degree in biological sciences from University of Essex, a master's degree in Biotechnology from Reading University and a PhD in Cell Biology from University College London. He is the holder of multiple U.S.-issued patents in the area of separations science.
Martin Smith ,自2021年8月起担任执行副总裁兼首席技术官。在加入IDEXX之前,他曾担任CyTiVA的副总裁和首席技术官,CyTiVA是DaaHER公司的一部分,从2020年8月到2021年7月。此前,Smith 博士在帕尔公司担任过各种领导职位,职责越来越重,最近一次是在2014年9月至2020年8月担任帕尔公司的首席技术官。Smith 博士曾在Pall担任高级副总裁,2010年至2014年担任Pall研发部副总裁,2008年至2010年担任Pall Medical研发部副总裁,2006年至2008年担任Pall生命科学研发部高级总监。Smith 博士获得了埃塞克斯大学生物科学的本科学位,来自雷丁大学的生物技术硕士学位和伦敦大学学院细胞生物学博士学位。他在分离科学领域拥有多项美国专利。
Martin Smith,has been Executive Vice President and Chief Technology Officer since August 2021. Prior to joining IDEXX, he served as Vice President and Chief Technology Officer of Cytiva, which is part of Danaher Corporation, from August 2020 to July 2021. Previously, Dr. Smith held various leadership positions with increasing responsibilities at Pall Corporation, most recently serving as Pall's Chief Technology Officer from September 2014 to August 2020. Dr. Smith's prior roles at Pall included Senior Vice President, Pall R&D from 2010 to 2014, Vice President, Research & Development, Pall Medical from 2008 to 2010 and Senior Director, Pall Life Science R&D from 2006 to 2008. Dr. Smith received an undergraduate degree in biological sciences from University of Essex, a master's degree in Biotechnology from Reading University and a PhD in Cell Biology from University College London. He is the holder of multiple U.S.-issued patents in the area of separations science.
Michael P. Johnson

Michael P. Johnson ,自2022年3月起担任高级副总裁兼首席人力资源官,领导全球人力资源部。在加入Idexx Laboratories, Inc.之前,Johnson 先生于1999年在雅培实验室有限公司开始了他的职业生涯,在那里他担任各种人力资源职位,年资不断增加,包括从2020年7月到2022年3月担任多元化和包容性部门副总裁,人力资源部门副总裁,2017年1月至2020年6月期间担任雅培糖尿病护理,2013年11月至2016年12月期间担任雅培医疗光学,2009年至2013年期间担任亚洲和欧洲各种国际业务的区域人力资源总监。Johnson 先生拥有伊利诺伊大学组织管理学的本科学位。


Michael P. Johnson,has been Idexx Laboratories, Inc. Senior Vice President and Chief Human Resources Officer since March 2022 and leads worldwide human resources. Prior to joining Idexx Laboratories, Inc. , Mr. Johnson began his career in 1999 at Abbott Laboratories, Inc., a Fortune 100 human healthcare company, where he held various human resources positions of increasing seniority, including serving as Divisional Vice President of Diversity and Inclusion from July 2020 to March 2022, Divisional Vice President, Human Resources, for Abbott Diabetes Care from January 2017 to June 2020 and for Abbott Medical Optics from November 2013 to December 2016, and Regional Human Resources Director for a variety of international operations in Asia, Latin America and Europe from 2009 to 2013. Mr. Johnson holds an undergraduate degree in Organizational Administration from the University of Illinois.
Michael P. Johnson ,自2022年3月起担任高级副总裁兼首席人力资源官,领导全球人力资源部。在加入Idexx Laboratories, Inc.之前,Johnson 先生于1999年在雅培实验室有限公司开始了他的职业生涯,在那里他担任各种人力资源职位,年资不断增加,包括从2020年7月到2022年3月担任多元化和包容性部门副总裁,人力资源部门副总裁,2017年1月至2020年6月期间担任雅培糖尿病护理,2013年11月至2016年12月期间担任雅培医疗光学,2009年至2013年期间担任亚洲和欧洲各种国际业务的区域人力资源总监。Johnson 先生拥有伊利诺伊大学组织管理学的本科学位。
Michael P. Johnson,has been Idexx Laboratories, Inc. Senior Vice President and Chief Human Resources Officer since March 2022 and leads worldwide human resources. Prior to joining Idexx Laboratories, Inc. , Mr. Johnson began his career in 1999 at Abbott Laboratories, Inc., a Fortune 100 human healthcare company, where he held various human resources positions of increasing seniority, including serving as Divisional Vice President of Diversity and Inclusion from July 2020 to March 2022, Divisional Vice President, Human Resources, for Abbott Diabetes Care from January 2017 to June 2020 and for Abbott Medical Optics from November 2013 to December 2016, and Regional Human Resources Director for a variety of international operations in Asia, Latin America and Europe from 2009 to 2013. Mr. Johnson holds an undergraduate degree in Organizational Administration from the University of Illinois.
Brian P. McKeon

Brian P. McKeon,自2014年1月起担任公司的执行副总裁、首席财务官和财务主管。他领导公司的金融和信息技术职能。2003年7月至2013年12月,McKeon先生担任了IDEXX的董事,包括董事会审计委员会主席和薪酬委员会成员。2007年4月至2013年12月,McKeon先生担任了Iron Mountain Incorporated(一家上市公司,在全球范围内提供信息保护和存储服务)的执行副总裁;2007年4月至2013年10月,担任Iron Mountain的首席财务官。2000年3月至2007年4月,McKeon先生担任了 was also Executive Vice President and Chief Financial Officer of The Timberland Company(一家上市公司,提供优质的户外鞋类、服装和配件)的执行副总裁和首席财务官、1991年至2000年,McKeon先生在PepsiCo Inc.担任过几个金融和战略计划职位,最近担任Pepsi-Cola在北美的金融副总裁。在加入PepsiCo之前, McKeon先生在Alliance Consulting Group担任战略顾问,在Coopers & Lybrand担任审计师。 McKeon先生拥有University of Connecticut的学士学位,和Harvard University的工商管理硕士学位。


Brian P. McKeon,has been Executive Vice President, Chief Financial Officer, and Treasurer since January 2014. He leads Idexx Laboratories, Inc. finance and investor relations functions, and has oversight responsibility for Idexx Laboratories, Inc. Water, OPTI Medical and Livestock, Poultry and Dairy businesses. Mr. McKeon previously had oversight responsibility over various functions, including Idexx Laboratories, Inc. corporate development, strategy, global operations and information technology functions and the Companion Animal Group business in Latin America. Mr. McKeon has served as a Director of Alkermes plc since December 2020, where he serves as Chair of the Financial Operating Committee and as a member of the Compensation Committee. Mr. McKeon served as a Director of IDEXX from July 2003 through December 2013, including serving as Chair of the Audit Committee and as a member of the Compensation Committee. He also served as a Director of athenahealth, Inc. from September 2017 to February 2019. Mr. McKeon was Executive Vice President of Iron Mountain Incorporated from April 2007 to December 2013 and Chief Financial Officer of Iron Mountain from April 2007 to October 2013. Mr. McKeon was also Executive Vice President and Chief Financial Officer of The Timberland Company from March 2000 to April 2007. From 1991 to 2000, Mr. McKeon held several finance and strategic planning positions with PepsiCo Inc. Mr. McKeon holds an undergraduate degree in Accounting from the University of Connecticut and an MBA with high distinction from Harvard University.
Brian P. McKeon,自2014年1月起担任公司的执行副总裁、首席财务官和财务主管。他领导公司的金融和信息技术职能。2003年7月至2013年12月,McKeon先生担任了IDEXX的董事,包括董事会审计委员会主席和薪酬委员会成员。2007年4月至2013年12月,McKeon先生担任了Iron Mountain Incorporated(一家上市公司,在全球范围内提供信息保护和存储服务)的执行副总裁;2007年4月至2013年10月,担任Iron Mountain的首席财务官。2000年3月至2007年4月,McKeon先生担任了 was also Executive Vice President and Chief Financial Officer of The Timberland Company(一家上市公司,提供优质的户外鞋类、服装和配件)的执行副总裁和首席财务官、1991年至2000年,McKeon先生在PepsiCo Inc.担任过几个金融和战略计划职位,最近担任Pepsi-Cola在北美的金融副总裁。在加入PepsiCo之前, McKeon先生在Alliance Consulting Group担任战略顾问,在Coopers & Lybrand担任审计师。 McKeon先生拥有University of Connecticut的学士学位,和Harvard University的工商管理硕士学位。
Brian P. McKeon,has been Executive Vice President, Chief Financial Officer, and Treasurer since January 2014. He leads Idexx Laboratories, Inc. finance and investor relations functions, and has oversight responsibility for Idexx Laboratories, Inc. Water, OPTI Medical and Livestock, Poultry and Dairy businesses. Mr. McKeon previously had oversight responsibility over various functions, including Idexx Laboratories, Inc. corporate development, strategy, global operations and information technology functions and the Companion Animal Group business in Latin America. Mr. McKeon has served as a Director of Alkermes plc since December 2020, where he serves as Chair of the Financial Operating Committee and as a member of the Compensation Committee. Mr. McKeon served as a Director of IDEXX from July 2003 through December 2013, including serving as Chair of the Audit Committee and as a member of the Compensation Committee. He also served as a Director of athenahealth, Inc. from September 2017 to February 2019. Mr. McKeon was Executive Vice President of Iron Mountain Incorporated from April 2007 to December 2013 and Chief Financial Officer of Iron Mountain from April 2007 to October 2013. Mr. McKeon was also Executive Vice President and Chief Financial Officer of The Timberland Company from March 2000 to April 2007. From 1991 to 2000, Mr. McKeon held several finance and strategic planning positions with PepsiCo Inc. Mr. McKeon holds an undergraduate degree in Accounting from the University of Connecticut and an MBA with high distinction from Harvard University.